China Resources Pharma finalises RMB2.00 billion third-tranche issuance of 2026 corporate bonds at 1.59% coupon

Bulletin Express

06/26

China Resources Pharmaceutical Group Limited (China Resources Pharma) has completed the public issuance of the third tranche of its 2026 corporate bonds through non-wholly-owned subsidiary China Resources Pharmaceutical Commercial Group Company Limited.

The latest tranche raised RMB2.00 billion with a three-year maturity and an annual coupon rate of 1.59%. Proceeds are earmarked for production-related expenditures, including working-capital replenishment, repayment of interest-bearing debt and project investments, in accordance with relevant regulations.

The transaction follows two earlier tranches announced on 27 March 2026 and 28 April 2026, bringing the company closer to fulfilling its 2026 bond programme. The board advised shareholders and potential investors to exercise caution when dealing in the company’s securities.

The announcement was issued on 26 June 2026 and signed by Chairman Mr. Bai Xiaosong on behalf of the board.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1143672213"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143672213\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143672213?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143672213","market":"us","top_or_hot":-1,"title":"China Resources Pharma finalises RMB2.00 billion third-tranche issuance of 2026 corporate bonds at 1.59% coupon","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (China Resources Pharma) has completed the public issuance of the third tranche of its 2026 corporate bonds through non-wholly-owned subsidiary China Resources Pharmaceutical Commercial Group Company Limited.</p>\n<p>The latest tranche raised RMB2.00 billion with a three-year maturity and an annual coupon rate of 1.59%. Proceeds are earmarked for production-related expenditures, including working-capital replenishment, repayment of interest-bearing debt and project investments, in accordance with relevant regulations.</p>\n<p>The transaction follows two earlier tranches announced on 27 March 2026 and 28 April 2026, bringing the company closer to fulfilling its 2026 bond programme. The board advised shareholders and potential investors to exercise caution when dealing in the company’s securities.</p>\n<p>The announcement was issued on 26 June 2026 and signed by Chairman Mr. Bai Xiaosong on behalf of the board.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Pharma finalises RMB2.00 billion third-tranche issuance of 2026 corporate bonds at 1.59% coupon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Pharma finalises RMB2.00 billion third-tranche issuance of 2026 corporate bonds at 1.59% coupon\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-06-26 19:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (China Resources Pharma) has completed the public issuance of the third tranche of its 2026 corporate bonds through non-wholly-owned subsidiary China Resources Pharmaceutical Commercial Group Company Limited.</p>\n<p>The latest tranche raised RMB2.00 billion with a three-year maturity and an annual coupon rate of 1.59%. Proceeds are earmarked for production-related expenditures, including working-capital replenishment, repayment of interest-bearing debt and project investments, in accordance with relevant regulations.</p>\n<p>The transaction follows two earlier tranches announced on 27 March 2026 and 28 April 2026, bringing the company closer to fulfilling its 2026 bond programme. The board advised shareholders and potential investors to exercise caution when dealing in the company’s securities.</p>\n<p>The announcement was issued on 26 June 2026 and signed by Chairman Mr. Bai Xiaosong on behalf of the board.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"華潤醫藥","start_time":0,"source_url":"","article_id":"1143672213","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143672213","pubTimestamp":1782474198,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (China Resources Pharma) has completed the public issuance of the third tranche of its 2026 corporate bonds through non-wholly-owned subsidiary China...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药完成2026年第三期20.0亿元公司债券发行，票面利率为1.59%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (China Resources Pharma) has completed the public issuance of the third tranche of its 2026 corporate bonds through non-wholly-owned subsidiary China Resources Pharmaceutical Commercial Group Company Limited.\nThe latest tranche raised RMB2.00 billion with a three-year maturity and an annual coupon rate of 1.59%. Proceeds are earmarked for production-related expenditures, including working-capital replenishment, repayment of interest-bearing debt and project investments, in accordance with relevant regulations.\nThe transaction follows two earlier tranches announced on 27 March 2026 and 28 April 2026, bringing the company closer to fulfilling its 2026 bond programme. The board advised shareholders and potential investors to exercise caution when dealing in the company’s securities.\nThe announcement was issued on 26 June 2026 and signed by Chairman Mr. Bai Xiaosong on behalf of the board.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}